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rights reserved.CARDIOVASCULAR DISEASE BURDEN IN
LATIN AMERICA AND THE CARIBBEAN
In the Americas, CVD represents about 38% of non-
communicable disease (NCD) deaths and is the leading
cause of death, with 1.6 million deaths per year, one-half
million occurring before age 70 [3]. Although mortality
due to CVD in the Americas declined 19.2% from 2000
to 2007, higher median CVD mortality was found in low-
income (242 per 100,000) and medium-income (186 per
100,000) countries, compared with high-income coun-
tries (154 per 100,000) [4]. Between 2000 and 2010,
premature CVD mortality (<70 years of age) in the
Americas decreased by 21%, with a statistically significant
2.5% average annual decline in the rate of change in the
final 5 years. Declines in mortality from ischemic vascular
disease (overall, 25%; men, 24%; women, 26%) and ce-
rebrovascular disease (overall, 27%; men, 26%; women,
28%) were observed during the first decade of this cen-
tury. These declines were not uniform across all coun-
tries, with notable disparities in country-specific
premature mortality rates (region average, 132.7 per
100,000), including rates above 200 per 100,000 in
Guyana, Trinidad and Tobago, the Dominican Republic,
Bahamas, and Brazil [5]. Although, substantial decreases
in CVD mortality rates have been seen in most regions,
including the Americas from 1990 to 2013, the CVD
burden, and specifically the absolute number of cases and
deaths have risen in some but not all countries of the
region [6]. CVD disproportionately affects the poorest
population sectors [7], affecting families, communities,
and governments due to treatment costs and potential
years of life and productivity lost due to premature death
and disability [8,9]. Therefore, the direct and indirectGLOBAL HEART, VOL. 13, NO. 2, 2018
June 2018: 83-91costs of these diseases absorb resources that could
otherwise be spent in health promotion efforts at the
community and clinical levels [7].
In terms of the global economic burden, direct and
indirect costs of CVD were estimated to be US$863 billion
in 2010, potentially rising to US$1.04 trillion by 2030
[10]. Even countries such as Brazil, Chile, Mexico,
Argentina, and Peru, which experienced some economic
growth in recent years, lack economic assets to efficiently
provide resources to prevent and manage CVD [11]. A
comprehensive approach to CVD prevention and man-
agement is needed for long-term improvements in car-
diovascular health. This report focuses on efforts to
improve secondary prevention using existing frameworks,
tailored to the Latin American and Caribbean (LAC)
context.THE FRAMEWORK OF
CVD SECONDARY PREVENTION
Secondary prevention of CVD can be defined as the use of
intensive risk-reduction therapies and adoption of healthy
lifestyle behaviors in patients with established coronary
and/or other atherosclerotic vascular diseases. This would
include peripheral artery disease, atherosclerotic aortic
disease, and carotid and cerebral artery disease with clinical
benefits of 75% estimated efficacy. Efficacy with these
outcomes has been assessed by a variety of outcomes,
including improved survival, reduced recurrent events, the
need for revascularization procedures, and improved
quality of life [12-14]. Risk-reduction therapies and healthy
lifestyle changes include pharmacological and non-
pharmacologic interventions. Examples of pharmacologic
interventions for these populations include antiplatelet
agents, beta-blockers, angiotensin-converting enzyme
(ACE) inhibitors or angiotensin-receptor blockers (ARB),
3-hydroxy-3-methy-glutaryl-coenzymeA reductase in-
hibitors (e.g., statins), and pharmaceutical therapy for
tobacco cessation. Examples of nonpharmacological in-
terventions include smoking cessation counseling, physical
activity, and healthy diet. Both pharmacologic and non-
pharmacologic interventions aim to reduce the probability83
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84of recurrent cardiovascular events in patients with clinically
evident atherosclerotic cardiovascular disease [15]. More-
over, clinical practice guidelines for the management of
care with appropriate updates have been periodically
published by several medical societies to guide physician
prescription of proven, effective treatments in compre-
hensive CVD care [12,16-23]. Optimal risk factor man-
agement through nonpharmacologically based approaches
(Table 2) may include tobacco cessation counseling, reg-
ular participation in physical activity, achieving a healthy
diet, limited alcohol intake, and weight management; with
clinical outcome improvements in blood pressure control,
lipid management, and diabetes control [12,15,24-28].
Although these interventions have been shown to be
effective, their uptake by patients can be challenging, and
clinical and public health programs are encouraged to
adapt resources to the culture and capability of those they
serve. Programs addressing these areas are often composed
of a multidisciplinary team of providers and should include
individual level interventions using targeted education and
behavior modification programs to counterbalance the
“continuum” of the atherosclerotic process. Population-
wide interventions (e.g., limiting exposure to secondhand
tobacco smoke, sodium reduction) to reduce exposures to
risk factors should complement individualized in-
terventions that support risk factor management.CVD SECONDARY PREVENTION IN LATIN AMERICA
AND THE CARIBBEAN: A SITUATION ANALYSIS
A large body of robust evidence to guide therapeutic de-
cision making and enhance long-term adherence after an
acute episode of CVD, such as ST-segment elevation
myocardial infarction, noneST-segment elevation acute
coronary syndromes, or revascularization procedures ex-
ists. Despite this, we frequently observe substantial dis-
crepancies between the evidence-based recommendations
and what is actually delivered in clinical practice. This can
be appropriately documented based on contemporary real-
world data on the use of beneficial secondary prevention
medications among several geographic regions, including
LAC. Examples include clinical as well as community-
based studies. The REACH (REduction of Athero-
thrombosis for Continued Health) registry included data
from North America, Europe, Australia, Asia, Latin Amer-
ica (Brazil, Chile, Mexico, Panama, Costa Rica, Dominican
Republic, Ecuador, Guatemala, and Peru), and the Middle
East. The use of secondary prevention medications was
ascertained among 32,247 patients. Among these patients,
a significant gap was detected between clinically indicated
and actual rates of use at the first visit assessment and after
3 years of follow-up: aspirin alone (baseline: 56.6% and 3-
year follow-up: 56.9%); aspirin plus another antiplatelet
agent (14.5% and 12.8%); other antiplatelet agents alone
(13.6% and 14.2%); and statins (68.3% and 71.9%) [29].
Compared with patients in North America in the REACH
registry, patients from Latin America and Asia were lessGLOBAL HEART, VOL. 13, NO. 2, 2018
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TABLE 2. Recommendations for secondary prevention as AHA/ACC guideline, 2011
Area for Intervention Goal
Smoking Complete cessation. No exposure to environmental tobacco smoke.
Blood pressure control <140/90 mm Hg
Lipid management Treatment with statin therapy; use statin therapy to achieve an LDL-C of <100 mg/dl; for very high-
risk patients an LDL-C <70 mg/dl is reasonable; if triglycerides are 200 mg/dl, noneHDL-C
should be <130 mg/dl, whereas noneHDL-C <100 mg/dl for very high-risk patients is
reasonable.
Physical activity At least 30 min, 7 days per week (minimum 5 days per week)
Weight management Body mass index: 18.5 to 24.9 kg/m2
Waist circumference: women <35 inches (<89 cm), men <40 inches (<102 cm)
Type 2 diabetes mellitus
management
Recommendations are for prevention of cardiovascular complications, based on lifestyle
modification, weight management, blood pressure control, lipid management, and
pharmacotherapy for all diabetes patients.
Medications based on
evidence
Must be considered based on clinical condition of the patient, but the combination of them should
be applied to all patients on secondary prevention: antiplatelet agents/anticoagulants; renin-
angiotensin-aldosterone system blockers; ACE inhibitors; ARB; aldosterone blockade; beta-
blockers.
Influenza vaccination Should be applied to all patients with cardiovascular disease an annual influenza vaccination
program.
Depression It is reasonable to screen for depression if patients have access to case management, in
collaboration with their primary care physician and a mental health specialist.
Cardiac rehabilitation All patients with ACS or postintervention procedures should be referred to a cardiac rehabilitation
program. Home-based programs have similar results as compared with supervised, center-based
program for low-risk patients.
ACC, American College of Cardiology; ACE, angiotensin-converting enzyme; ACS, acute coronary syndrome; AHA, American Heart Association; ARB,
angiotensin-receptor blocker; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
gRECSjlikely to be fully adherent to guideline-based treatments at
4 years [30]. Data from the large community-based PURE
(Prospective Urban Rural Epidemiology) study have pro-
vided relevant assessment on the use of secondary pre-
vention therapies across broad geographic and income
levels. The use of effective secondary preventive medica-
tions (antiplatelet agents, beta-blockers, ACE inhibitors or
ARB, and statins) in 153,996 adults ages 35 to 70 years
with a history of coronary heart disease or stroke, from
rural and urban communities in countries classified at
various income levels by the World Bank has been evalu-
ated. Few patients in the study were taking antiplatelet
agents (25.3%), beta-blockers (17.4%), ACE inhibitors or
ARB (19.5%), or statins (14.6%). Furthermore, use was
lowest in low-income countries (8.8%, 9.7%, 5.2%, and
3.3%, respectively) [31].
Recent data from the PURE study have also shown
poor adoption of healthy lifestyle behaviors among those
with known CVD, emphasizing the urgent need of efforts
to implement the nonpharmacologically based in-
terventions. For example, among 7,519 individuals with
self-reported coronary heart disease or stroke, a substantial
proportion continued some level of tobacco use following
their event (18.5%), only 35.1% participated in high levels
of physical activity and only about 40% had diets classified
as healthy. Changes in dietary habits may be a significant
barrier in many environments, particularly low-incomeGLOBAL HEART, VOL. 13, NO. 2, 2018
June 2018: 83-91countries. In addition, 14% did not undertake any of
these 3 key healthy lifestyle behaviors and only 4.3% were
classified as achieving all 3 recommended healthy behav-
iors. Variations in participation in healthy lifestyle behav-
iors were seen among different subgroups. For example,
whereas over 50% reported smoking cessation during the
period assessed, differences were noted among high-
income countries (74.9%), upper-middle-income coun-
tries (56.5%), low-middle-income countries (42.6%), and
low-income countries (38.1%) [32]. The existing evidence
shows that lifestyle modifications to reduce the risk of
recurrent CVD events are not being maximized, and these
could be implemented alongside long-term pharmacolog-
ical management of CVD. However, current approaches to
modifying lifestyle behaviors, based on individual coun-
seling, are expensive and only modestly effective, particu-
larly among lower income countries, with significant
barriers in health system and clinical capacity, broader
approaches should be considered [31].
Overall, each year, millions of individuals survive
ischemic heart disease or stroke events. This creates sub-
stantial clinical and public health challenges in the provi-
sion of CVD risk factor management, availability and
affordability of effective therapies, adherence to prescribed
medications, and available financial and human resources
to care for individuals. Secondary prevention of CVD re-
quires a comprehensive system that includes increased85
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86patient awareness, prescription of evidenced-based treat-
ments using standardized approaches, patient adherence,
and functional health systems; all of which are influenced
by local socioeconomic factors. A fundamental aspect of
improving CVD care is the concept of individual and sys-
tem level factors being strongly influenced by the existence
of effective national policies aimed to control NCD. Many
efforts had been made by international organizations, such
as the World Health Organization (WHO) and the Pan
American Health Organization (PAHO), along with na-
tional organizations and medical societies, to prevent
recurrence of CVD events in LAC by means of national and
regional policies. Countries in the region have engaged in
implementing those policies supported by WHO and
PAHO; however, there is much to be done to reduce the
high burden of disease associated with CVD in LAC [33]
Due to the existing economic diversity within and across
the region, large geographic density and countries in
different stages of epidemiological transition, LAC consti-
tutes a vast field to build efficient and complementary
models for secondary prevention of CVD.ROADMAP FOR SECONDARY PREVENTION IN
LATIN AMERICA AND THE CARIBBEAN
The World Heart Federation (WHF) Roadmaps are aligned
with the WHO goal of reducing premature mortality from
CVD by at least 25% by 2025, and it may be viewed as a
model to be locally customized for countries into currently
established CVD prevention programs or to build imple-
mentation strategies where an efficient program is not yet
implemented. The Secondary Prevention Roadmap in LAC
aims to optimize actions to prevent and control CVD. Based
on clear evidence of effectiveness, including feasibility and
cost effectiveness, a practical roadmap identifies potential
barriers (roadblocks) to implementation of prevention and
control efforts and potential solutions for bypassing those
barriers [15]. In some circumstances, proven therapies are
neither available, nor affordable, and increased availability
of proven therapies by means of expanded health coverage
would potentially address that roadblock [34]. Finally,
implementation of information and communication tech-
nology concerning the use of key therapies from simplified
recommendations would maximize use of available re-
sources for better treatment and patient adherence. The e-
health technology has the potential to be incorporated into
daily clinical practice due to its low cost and being simple
and widely available. About Latin America, around 150
million individuals use smartphones, and there are pre-
dictions that this number will increase up to 245 million
users in 2019. Therefore, there is a good opportunity and
potential utility of e-health technologies, particularly in
terms of secondary prevention strategies in Latin America.
Two main actions are necessary to achieve the desired
target for secondary prevention. First, priority interventions
provided in a standardized algorithm (pharmacologic
availability and use: ACE inhibitors, aspirin, statins, beta-blockers, tobacco cessation agents, and nonpharmacologic
strategies that facilitate lifestyle modification, particularly
smoking cessation) should be used broadly in a standard-
ized manner by multidisciplinary teams in diverse settings.
Second, systems of care should be structured to improve the
likelihood of patient adherence to these interventions [15].
Table 3 identifies roadblocks and potential solutions for
LAC that were the result of a joint consultation meeting
between several international organizations (PAHO, WHF,
the Latin American Society of Hypertension, the Inter-
American Society of Cardiology [IASC], the Caribbean
Public Health Agency, the Centers for Disease Control and
Prevention), and representatives of Ministries of Health of
selected countries (Brazil, Chile, Cuba) held in São Paulo,
Brazil, at the end of 2015. This joint consultation, which
reviewed the applicability of the WHF Global Roadmap on
Secondary Prevention for Latin America and explored op-
portunities to improve secondary prevention, concluded
that WHF Roadmap framework is well aligned with the
WHO strategy and priorities for NCD/CVD management as
well as with the priorities of many other relevant global and
regional organizations in this particular matter. In addition,
this consultation highlighted that the WHF Roadmap offers
an important opportunity to work in the coordinated
manner at local and regional levels to coordinate efforts
among between partners to scale up secondary prevention
of CVD in the Americas.
The following actions should be prioritized to obtain
the desirable outcomes (Figure 1): 1) integration of CVD
secondary prevention interventions into the general
framework of CVD/NCD management; 2) increasing the
availability of health care professionals to provide recom-
mendations to patients with known CVD; 3) simplifying
the treatment of patients with known CVD; 4) ensuring
that health care professionals are aware of and follow rec-
ommendations; 5) increasing the availability and afford-
ability of key priority interventions; 6) helping patients to
adhere to recommendations; 7) strengthening the gover-
nance of health care systems to enhance prevention; and 8)
strengthening health information systems [15].LATIN AMERICAN CVD PREVENTION AND
CONTROL PRIORITIES
In 2006, in response to the regional and global concern
about NCD, the Directing Council of PAHO approved a
comprehensive regional plan for the prevention and con-
trol of NCD [35]. This program was operationalized
through biannual plans aimed at achieving specific objec-
tives, which included 4 lines of action: integrated man-
agement of NCD and risk factors; health promotion and
disease prevention; surveillance; and policy and advocacy
[33]. Since then, significant progress in implementing na-
tional chronic disease programs has been reported in the
majority of countries [33].
In 2010, a regional consultation on cardiovascular
health, led by PAHO, proposed a core set of priorityGLOBAL HEART, VOL. 13, NO. 2, 2018
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TABLE 3. Roadblocks and potential solutions to achieve appropriate cardiovascular secondary prevention targets in LAC
Roadblock Potential Solutions
Health care systems do not
efficiently track patients
with known CVD; poor/
lack of integration
between CVD referral
centers and primary care.
Establish integrated
information systems
across different levels of
health care; create a
unique ID to
appropriately track those
with CVD.
Physician/hospital report of
patient’s clinical
diagnoses and status,
medications prescribed,
summary of
postdischarge plan for
long-term management
of care.
Referral to rehabilitation
services; improve
schedule of follow-up
visits at outpatient clinics
Education provided to the
patient and family: the
disease and possible
complications,
importanceof the use of
specific medications,
adoption of healthy
lifestyle
Patients with known CVD do
not have access to the
health care system.
Increase appropriate access
to the health care system;
create an efficient plan
for continuous tracking
system to minimize cases
lost to follow-up.
Strengthen the role of the
primary health care
system to support
secondary prevention of
CVD rare health system
level on cardiovascular
secondary prevention;
similar solutions to first
roadblock as described.
Expand clinic operating
hours; schedule first and
follow-up visit in
collaboration with
patients; diversify
locations of health care
units, especially in rural
communities.
Lack of health care
professionals to prescribe
priority interventions.
Increase the number of
professionals to prescribe
the interventions.
Increase task-shifting
(nonphysician based
program to deliver
priority interventions to
populations of interest by
transferring tasks to other
team members, as
appropriate).
Guidelines are not available
or recommendations are
too complex.
Develop or translate a simple
set of recommendations
for the primary care
workforce.
Clinical decision support
systems to guide
decision-making process
and remind providers of
key priority interventions.
Utilizing e-health to its
maximum capacity.
Health care professionals are
not aware of guidelines.
Targeted education of CVD
secondary prevention to
staff, with associated
continuing education
credits.
Quality improvement review
of recommended
interventions, follow-up,
and feedback.
Clinical decision support
systems (e-health) to
increase awareness.
Health care professionals are
aware but do not follow
guidelines.
Local opinion leader to teach,
guide, and discuss the
importance of guideline-
driven care.
Assess feasibility of
implementing financial
incentives.
Clinical decision support
systems (e-health);
implement recognition
programs to drive
positive change.
Priority interventions are not
available.
Ensure priority interventions
are included in the
national list of essential
medicines.
Establish a “core set” of
medications; ensure that
this core set is available
at the community level.
Priority interventions are not
affordable.
Promote the use of quality
generic medications;
assess feasibility of
polypill/polycapsule to
enhance universal
coverage and improve
long-term adherence.
Promote local manufacturing;
bulk purchasing and/or
efficient system to
streamline medication
supply; choose low-cost,
high-quality alterative.
Provide financial and social
support for patients to
purchase priority
interventions.
(continued)
gRECSj
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TABLE 3. Continued
Roadblock Potential Solutions
Patients are not aware of the
importance of and need
for long-term treatment.
Engage diverse health care
staff (e.g., pharmacy,
nurses) to education
patients and family about
the health condition;
promote continuous
education on
consequences, daily
activities of living, and
impact on survival.
Public campaigns;
performance measures as
metrics to inform patients
and family; provider point
of care decision prompts
in risk factor review and
medication adherence.
Empower patients to have a
key role in the decision-
making process (patient
advocacy), sharing
comments, and thoughts
with health care
providers.
Patients do notremember to
follow recommendations.
Use information and
communication
technology to remind
patients about key and
simple recommendations
(mHealth).
Shift conversation away from
directly blaming patient
to one of mutual
understanding of need for
lifestyle changes to
manage and improve
chronic condition.
Use patient-nominated,
nonprofessional
treatment supporters
(family and close friends
to come to the first visit
at the outpatient clinic
after the CV event).
Encourage community
engagement and
ownership of health
promotion activities
through integration of
new technologies.
Patients with low health
literacy who do not know
what medication to take.
Develop easy to interpret
medication labels (e.g.,
symbols for dosing) and
educational materials.
Include education of broader
social support network,
including family
members.
CV, cardiovascular; CVD, cardiovascular disease; LAC, Latin America and Caribbean.
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88interventions to improve cardiovascular health in the re-
gion and, since then, much progress has been reported.
Policies related to improvements in smoke-free spaces were
most likely to be implemented. Progress was apparent in
surveillance of risk factors, actions to improve the quality
of mortality data, and access to medication for hyperten-
sion among disadvantaged populations. However, signifi-
cant challenges persist in many priority areas. For instance,
on the prevention side, less than one-half of countries re-
ported more focus and resources for cardiovascular health
components of the NCD plans. What was also evident in
that report was the limited progress on the clinical man-
agement of CVD. For example, less than 50% of the
countries reported clear progress on the following:
emphasis of therapeutic control of hypertension; CVD risk
assessment in primary care; public health programs for
early recognition of CVD; institutional incentives for doc-
tors to use clinical practice guidelines in hypertension
management and for quality improvement of acute coro-
nary syndrome [36].
PROPOSAL FOR A REALISTIC AND EFFICIENT
PREVENTION COALITION PLAN IN LATIN AMERICA
Taking into account the heterogeneity of health systems,
management strategies for CVD prevention, and patient
adherence in LAC, a proposal for a coalition toward an
efficient and integrated prevention plan will not be an easy
task; however, this is indeed feasible. A common,
comprehensive, regional, and country-applicable agenda is
urgently needed and highly desirable for secondaryprevention of CVD in LAC. To address the high burden of
CVD in the region, a coalition plan should be developed.
This would include the integrated efforts of clinical medi-
cine, public health and health professional societies and
organizations, government at all levels (federal, state, and
municipal), patient organizations, universities, private ini-
tiatives, and international organizations such as PAHO and
WHF. The guarantee of availability and accessibility of an
essential set of medications is critical to moving forward
with the secondary prevention of the CVD agenda. In this
regard, the role of PAHO Strategic Fund would be relevant
to support the efforts of countries to improve the access to
high-quality and affordable, low-cost medications [37].
It would be very desirable that following this joint
consultation meeting, the LAC region can move toward the
construction of a regional plan to scale up the imple-
mentation of the CVD secondary prevention. Such a plan
should start with a situational analysis in each country to
properly and reliably assess the current landscape of sec-
ondary CVD prevention. The plan should focus on clear
and measurable objectives, contain straightforward imple-
mentation actions, and include a core set of indicators for
monitoring and evaluation.
SIMPLE AND PRACTICAL GUIDELINES FOR
HEALTH CARE PROVIDERS
Guideline-based recommendations continue to be under-
used, and some observational studies have shown that low
implementation in daily practice is associated with the high
degree of complexity of the recommendations [28,29,38].GLOBAL HEART, VOL. 13, NO. 2, 2018
June 2018: 83-91
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FIGURE 1. Health system requirements to achieve secondary prevention
targets. Reproduced with permission from Perel et al. [15].
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As a result, patients fail to benefit optimally from advances
in health care and are exposed to unnecessary risks, and
health care systems are exposed to unnecessary expendi-
tures. The utilization of clinical practice guidelines is
influenced by local barriers or facilitators for the individual
clinician and the professional context. There are gaps be-
tween knowledge and application, and these could be
linked to: 1) guidelines characteristics (e.g., format,
external validity, and scientific basis); 2) physician factors
that include knowledge, training, and agreement with
guidelines; and 3) both physician and organizational en-
vironments [38]. Francke et al. [39] suggested that
guidelines that are easy to understand and simple to use in
daily practice are more likely to be fully implemented.
Moreover, various characteristics of patients, health care
professionals, and the environment may influence guide-
line implementation. It seems clear that effective strategies
to improve guideline adherence that are based on multiple
domains and broader approaches are more likely to be
successful. WHO has promoted the use of a Package of
Essential Noncommunicable disease interventions for pri-
mary health care in low-resource settings. In the context of
CVD secondary prevention, the WHO Package of Essential
Noncommunicable [40] should be considered as a simple
and practical tool for health care providers that could be
customized to address local needs. Technical guidance
packages from WHO should also be considered to guide
interventions, including those focused on CVD prevention
and management (e.g., Global HEARTS [Technical Package
For Cardiovascular Disease Management In Primary Health
Care]), complemented by activities focused on sodium
reduction (e.g., SHAKE [Technical Package For Salt
Reduction]) and tobacco cessation (MPOWER [Technical
Package To Defeat The Global Tobacco Epidemic]) [41].FINAL CONSIDERATION
CVD imposes a heavy and lifelong burden in LAC. Avail-
ability of scientific evidence confirming efficacy of phar-
macological and nonpharmacological interventions
requires appropriate translation and implementation to
fully recognize their benefits. The WHF 25  25 Roadmap
aiming at reducing premature cardiovascular mortality,
globally, includes 3 major components: smoking; hyper-
tension; and cardiovascular secondary prevention. To
achieve efficiently the proposed target, a coalition
including academic, government, health organizations,
private stakeholders, and civil society, including nongov-
ernment organizations, must work together toward a better
and more efficient system for cardiovascular care delivery
in LAC. Therefore, there is a clear role for PAHO, WHF,
and organizations such as the Inter-American Society of
Cardiology to be responsible for organizing and harmo-
nizing the CVD secondary prevention in Latin America. In
that context, the IASC would have a crucial role leading the
National Cardiology Societies in Latin America.GLOBAL HEART, VOL. 13, NO. 2, 2018
June 2018: 83-91Regarding the role of primary care providers on the
care delivery in substantial proportion of secondary pre-
vention, especially outside the large cities and in poorer
regions where there are fewer cardiologists, understanding
and proposing how they might be reached and included in
these efforts represents a key challenge. In fact, we would
like to suggest that based on the 25  25 Roadmap
launched in Brazil, the Family Health Strategy, linked to
the Universal Health Coverage of the Brazilian Health
System, should definitely include health workers in order
to identify patients with secondary prevention eligibility
and to reassure the best possible adherence rates for
evidence-based medications. Consequently, the inclusion
of the health system component, ideally through health
workers for the implementation of strategies for CVD
secondary prevention is highly recommended for a suc-
cessful nationwide preventive program.
Finally, nongovernmental organizations serve as stra-
tegic partners and can support and deliver robust technical
assistance. Such technical assistance must be evidence-
based and action-oriented and include the CVD preven-
tion and management. The customization of the WHF
Roadmaps are complementary to the WHO Global Action
Plan for NCD prevention and control, and their imple-
mentation in LAC will allow us to positively influence the
significant burden of CVD over the next 10 years.89
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